Related Experiment Video

Updated: Sep 29, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

863

Does Losartan reduce the severity of COVID-19 in hypertensive patients?

Mohammadreza Mirjalili1, Moslem Taheri Soodejani2, Mehdi Raadabadi3

  • 1Internal Medicine Department, Medical College, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

BMC Cardiovascular Disorders
|March 20, 2022
PubMed

Insights

Losartan significantly reduced the risk of death in hypertensive patients with COVID-19 by over five times. Further research is recommended to explore blood pressure medications

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • The COVID-19 pandemic presents a global health challenge.
  • The role of various medications in managing COVID-19 outcomes remains unclear.
  • Hypertension is a common comorbidity associated with severe COVID-19 outcomes.

Purpose of the Study:

  • To investigate the impact of losartan on COVID-19 mortality rates.
  • To evaluate losartan's potential protective role in hypertensive patients diagnosed with COVID-19.

Main Methods:

  • An analytical study was conducted with 1458 patients diagnosed with COVID-19.
  • Data from hypertensive patients (n=280) who tested positive for SARS-CoV-2 (n=179) were analyzed.
  • Statistical methods included descriptive statistics, chi-square, Fisher's exact test, t-test, and logistic regression.

Main Results:

  • Hypertensive patients using losartan demonstrated a significantly lower mortality risk (odds ratio > 5, P = 0.003).
  • Losartan showed a trend towards a protective role in preventing COVID-19 in hypertensive patients, though not statistically significant (P = 0.86).

Conclusions:

  • Losartan use is associated with a reduced chance of mortality among hypertensive patients with COVID-19.
  • Larger-scale studies and laboratory investigations are recommended to further elucidate the effects of losartan and other antihypertensive drugs on COVID-19 outcomes.
Abstract

Keywords:
Blood pressure/hypertensionLosartanMortalitySARS-CoV-2

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
542
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
958
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
870
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
67
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36